RESUMEN
Chronic hepatitis D is caused by coinfection of hepatitis B and hepatitis D virus. While HDV is the dominant virus over HBV in the majority of cases, mechanisms and consequences of viral dominance are largely unknown. We aimed to investigate associations between viral dominance patterns and patients' characteristics and inflammatory features; 109 HDV-infected patients treated with PEG-IFNa-2α within the international multicentre, prospective HIDIT-2 trial were studied. Patients were classified as D- or B-dominant if the viral load of one virus exceeded that of the other virus by more than 1log10 . Otherwise, no viral dominance (ND) was described. We used Luminex-based multiplex technology to study 50 soluble immune mediators (SIM) in pretreatment samples of 105 HDV RNA-positive patients. Dominance of HDV was evident in the majority (75%) of cases. While only 7% displayed B-dominance, 17% showed nondominance. D-dominance was associated with downregulation of 4 interleukins (IL-2ra, IL-13, IL-16 and IL-18) and 5 chemokines/cytokines (CTACK (CCL27), MCP-1 (CCL2), M-CSF, TRAIL and ICAM-1) while no analyte was increased. In addition, D-dominance could be linked to a delayed HDV RNA response to pegylated interferon as patients with B-dominance or nondominance showed higher early HDV RNA responses (61% at week 12) than D-dominant patients (11%; P < .001). In conclusion, this study revealed unexpected effects of viral dominance on clinical and immunological features in chronic hepatitis delta patients. Individualizing PEG-IFNa-2α treatment duration should consider viral dominance. Overall, our findings suggest an activated but exhausted IFN system in D-dominant patients.
Asunto(s)
Antivirales/uso terapéutico , Virus de la Hepatitis B/fisiología , Hepatitis D Crónica/tratamiento farmacológico , Hepatitis D Crónica/virología , Virus de la Hepatitis Delta/fisiología , Interferón-alfa/uso terapéutico , Polietilenglicoles/uso terapéutico , Adulto , Ensayos Clínicos como Asunto , Citocinas/sangre , ADN Viral/sangre , Femenino , Antígenos de Superficie de la Hepatitis B/sangre , Virus de la Hepatitis B/genética , Virus de la Hepatitis B/inmunología , Hepatitis D Crónica/inmunología , Virus de la Hepatitis Delta/genética , Virus de la Hepatitis Delta/inmunología , Humanos , Hígado/patología , Masculino , Persona de Mediana Edad , ARN Viral/sangre , Proteínas Recombinantes/uso terapéutico , Factores de Tiempo , Resultado del Tratamiento , Carga Viral , Adulto JovenRESUMEN
BACKGROUND: There is reason to believe that the diagnosis of septic and toxic shock, as indicated on the death certificate, cannot be confirmed as the cause of death without autopsy and subsequent histological analysis. The external examination of the corpse can therefore not represent the sole basis for a reliable statement about the infection status of a corpse, e. g. as a prerequisite for embalming. MATERIAL AND METHODS: The validity of autopsy in determining septic and toxic shock as the cause of death is demonstrated in 7 exemplary cases. RESULTS: Decades of experience in a university pathology institute have shown that an external examination of the corpse alone is not suitable for certifying the cause of death if an infectious disease is suspected. Consequently, only autopsy with subsequent histological analysis provides reliable statements on the etiopathogenesis of the underlying process. Possible problems and discrepancies between clinical and pathological diagnoses are discussed on the basis of several cases with or without autoptic confirmation of the septic shock. The case of a missionary from Africa infected with Lassa virus serves to point out the seriousness of the threat an undiagnosed infection may represent to the attending staff. CONCLUSION: During the treatment of patients suspected to have an infectious cause of fever of unknown origin, compliance with the usual safety regulations, including adequate disinfecting measures, is essential. In cases with fatal outcome, not infrequently under the clinical picture of a septic and toxic shock, autopsy should be regularly performed to confirm the type of infection and the infectious cause of death. Rapid and open communication between the professional groups involved plays a crucial role in this process.
Asunto(s)
Autopsia , Causas de Muerte , Choque Séptico/patología , Adolescente , Adulto , Anciano , Certificado de Defunción , Diagnóstico Diferencial , Embalsamiento , Femenino , Humanos , Comunicación Interdisciplinaria , Colaboración Intersectorial , Fiebre de Lassa/patología , Masculino , Persona de Mediana Edad , Misioneros , Insuficiencia Multiorgánica/patología , Reproducibilidad de los Resultados , Síndrome de Respuesta Inflamatoria Sistémica/patologíaRESUMEN
The chronic course of hepatitis E virus (HEV) infections in orthotopic liver transplant (OLT) recipients has been described previously, but prospectively collected data are rare. We aimed to study the role of chronic hepatitis E in OLT in a real-life setting. Therefore, 287 adult OLT recipients (169 male [59%], median age 56 years) were prospectively tested by HEV polymerase chain reaction assay (lower level of detection = 10 IU/mL), irrespective of their level of liver enzymes. In 4 patients (1.4%), chronic HEV infection was diagnosed. All 4 patients were male, and their age (median 48.5 years), the time since transplantation (median 45.5 months), and bilirubin level (median 0.6 mg/dL) did not differ significantly from the total cohort. However, alanine transaminase and aspartame transaminase levels were significantly higher in HEV-infected patients (75-646 U/L, median 216 U/L and 68-317 U/L, median 108 U/L) than in non-infected patients (6-617 U/L, median 41 and 6-355 U/L, median 36; P = 0.004 and 0.040, Mann-Whitney test). In 3 patients, liver biopsy was performed and revealed signs of inflammation and chronic liver disease, as enlarged densely infiltrated portal tracts with mild-to-moderate interface hepatitis. All infected patients were treated with ribavirin with the starting dose adjusted to renal function (400-800 mg/day). In 2 patients, dose reduction was necessary. Transaminases normalized in all 4 patients, and all patients cleared their infection within 3 months of ribavirin treatment. However, 1 patient experienced viral relapse 12 weeks after discontinuation. Ribavirin medication was re-started and viral clearance occurred within 8 weeks and persisted. Sequence analysis of the HEV genome of this patient revealed that he was infected with an HEV variant, which recently has been shown to have a reduced response to ribavirin in cell culture. The risk of chronic HEV infections in OLT recipients in low-endemic countries should not be overestimated. No case of chronic hepatitis E was observed in patients with normal liver enzymes, indicating that general screening of all OLT recipients is not necessary. However, if chronic hepatitis E develops, it can be treated efficiently with ribavirin.
Asunto(s)
Hepatitis E/diagnóstico , Hepatitis Crónica/diagnóstico , Trasplante de Hígado , Complicaciones Posoperatorias/diagnóstico , Adolescente , Adulto , Anciano , Antivirales/uso terapéutico , Femenino , Hepatitis E/tratamiento farmacológico , Hepatitis E/etiología , Hepatitis Crónica/tratamiento farmacológico , Hepatitis Crónica/etiología , Humanos , Masculino , Persona de Mediana Edad , Complicaciones Posoperatorias/tratamiento farmacológico , Complicaciones Posoperatorias/etiología , Estudios Prospectivos , Ribavirina/uso terapéutico , Resultado del Tratamiento , Adulto JovenRESUMEN
Chronic hepatitis C patients often fail to respond to interferon-based therapies. This phase III study aimed at confirming the efficacy and safety of glycyrrhizin in interferon + ribavirin-based therapy non-responders. A randomised, double-blind, placebo-controlled, comparison of glycyrrhizin, administered intravenously 5×/or 3×/week, and 5×/week placebo for 12 weeks to 379 patients, was followed by a randomised, open comparison of glycyrrhizin i.v. 5×/versus 3×/week for 40 weeks. Primary endpoints were: (1) the proportion of patients with ≥50% ALT (alanine aminotransferase) reduction after 12 weeks double-blind phase, and (2) the proportion of patients with improvement of necro-inflammation after 52 weeks as compared with baseline. The proportion of patients with ALT reduction ≥50% after 12 weeks was significantly higher with 5×/week glycyrrhizin (28.7%, P < 0.0001) and 3×/week glycyrrhizin (29.0%, P < 0.0001) compared with placebo (7.0%). The proportion of patients with improvement in necro-inflammation after 52 weeks was 44.9% with 5×/week and 46.0% with 3×/week, respectively. Glycyrrhizin exhibited a significantly higher ALT reduction compared to placebo after 12 weeks of therapy and an improvement of necro-inflammation and fibrosis after 52-weeks treatment. Generally, glycyrrhizin treatment was well tolerated.
Asunto(s)
Antiinflamatorios/administración & dosificación , Antiinflamatorios/efectos adversos , Ácido Glicirrínico/administración & dosificación , Ácido Glicirrínico/efectos adversos , Hepatitis C Crónica/tratamiento farmacológico , Adulto , Alanina Transaminasa/sangre , Método Doble Ciego , Femenino , Humanos , Interferón-alfa/uso terapéutico , Hígado/patología , Masculino , Persona de Mediana Edad , Placebos/administración & dosificación , Resultado del TratamientoRESUMEN
Liver allograft pathology continues to play an important role in the diagnosis and management of complications in the course of liver transplantation. This article summarizes important patterns of liver damage and also considers new aspects of transplant pathology from the literature. In the context of transplant rejection, late cellular rejection has aroused new interest. Histopathological changes in late rejection differ from acute cellular rejection and there seem to be similarities to de novo autoimmune hepatitis and idiopathic post-transplant hepatitis. Central perivenulitis is a typical change in late cellular rejection and should be differentiated from central toxic necrosis. Other important areas of transplant pathology include vascular and biliary changes resulting from surgical complications or as sequelae of immunosuppressive therapy. Furthermore, disease recurrence plays an important role and combined patterns of disease poses a challenge for the pathologist.
Asunto(s)
Rechazo de Injerto/patología , Hepatopatías/patología , Trasplante de Hígado/patología , Hígado/patología , Biopsia , Diagnóstico Diferencial , Secciones por Congelación , Rechazo de Injerto/clasificación , Rechazo de Injerto/inmunología , Hepatitis Autoinmune/inmunología , Hepatitis Autoinmune/patología , Hepatitis Crónica/inmunología , Hepatitis Crónica/patología , Humanos , Inmunidad Celular/inmunología , Hígado/inmunología , Hepatopatías/inmunología , Trasplante de Hígado/inmunología , Pronóstico , Factores de Riesgo , Inmunología del Trasplante/inmunologíaRESUMEN
Human cytomegalovirus, a double-stranded DNA virus, is a member of the Herpesviridae family with high rates of transmission. Primary infection is often asymptomatic and leads to life-long latency. Reactivation may induce different organ manifestations, particularly in the setting of immunosuppression. Histopathologically, the virus can be detected by light microscopy. Different cell populations in different organs are transformed into"owl's eye" cells, which are pathognomonic. Immunohistochemistry and electron microscopy can be applied as complementary methods. Various PCR approaches in molecular pathology including nested PCR, capture probe ELISA-PCR and real time PCR confer HCMV tests high sensitivity and specificity. The present article discusses the methods of pathological diagnostic approaches and describes organ manifestations of HCMV.
Asunto(s)
Infecciones por Citomegalovirus/patología , Biopsia , Citomegalovirus/genética , Infecciones por Citomegalovirus/congénito , Ensayo de Inmunoadsorción Enzimática , Femenino , Genes Virales/genética , Humanos , Inmunohistoquímica , Hibridación in Situ , Cuerpos de Inclusión Viral/patología , Recién Nacido , Microscopía Electrónica , Infecciones Oportunistas/patología , Trasplante de Órganos , Reacción en Cadena de la Polimerasa , Complicaciones Posoperatorias/patología , Embarazo , ARN Viral/genética , Reacción en Cadena en Tiempo Real de la Polimerasa , Activación Viral/fisiologíaRESUMEN
Soluble cytokine receptors modulate the activity of their cognate ligands. Interleukin (IL)-6 in association with the soluble IL-6 receptor (sIL-6R) can activate cells expressing the gp130 signal transducer lacking the specific IL-6R. To investigate the function of the IL-6-sIL-6R complex in vivo and to discriminate the function of the IL-6-sIL-6R complex from the function of IL-6 alone, we have established a transgenic mouse model. Double-transgenic mice coexpressing IL-6 and sIL-6R were generated and compared with IL-6 and sIL-6R single-transgenic mice. The main phenotype found in IL-6-sIL-6R mice was a dramatic increase of extramedullary hematopoietic progenitor cells in liver and spleen but not in the bone marrow. In IL-6 single-transgenic mice and sIL-6R single-transgenic mice no such effects were observed. The high numbers of hematopoietic progenitor cells were reflected by a strong increase of peripheral blood cell numbers. Therefore, activators of the gp130 signal transducer like the IL-6-IL-6R complex may represent most powerful stimulators for extramedullary hematopoietic progenitor cells. gp130 activators may become important for the expansion of hematopoietic progenitor cells in vivo and in vitro.
Asunto(s)
Células Madre Hematopoyéticas/citología , Interleucina-6/genética , Animales , Antígenos CD/metabolismo , Peso Corporal , Diferenciación Celular , División Celular , Separación Celular , Receptor gp130 de Citocinas , Citometría de Flujo , Células Madre Hematopoyéticas/metabolismo , Humanos , Inmunohistoquímica , Hígado/patología , Glicoproteínas de Membrana/metabolismo , Ratones , Ratones Transgénicos , Tamaño de los Órganos , Transducción de Señal , Bazo/patologíaRESUMEN
Alcoholic fatty liver (AFL) as well as non-alcoholic fatty liver (NAFL) are characterised by deposition of lipids into hepatocytes. The diagnosis of steatosis is made if lipid deposition exceeds 5 % of hepatocytes, in case of more than 50 % it is called "fatty liver". An additional inflammatory reaction, with ballooning of hepatocytes, leads to alcoholic steatohepatitis (ASH) or non-alcoholic steatohepatitis (NASH). Both ASH or NASH may lead to fibrosis or cirrhosis. To date in clinical practice it is not possible to differentiate between steatosis and steatohepatitis just on the basis of non-invasive tests. Steatohepatitis is present if, along with steatosis, both inflammatory infiltrates of mixed cells in the small liver lobules and liver cell injury in terms of ballooning can be detected. Liver biopsy represents the "gold standard" for confirming the diagnosis and to determine inflammatory activity and potential fibrosis of fatty liver disease. Indications for biopsy should take into account the possible information and its consequences as compared to expense and complication rate and therefore should be assessed in the clinical context.
Asunto(s)
Biopsia con Aguja/métodos , Hígado Graso/diagnóstico , Hígado Graso/patología , HumanosRESUMEN
Both alcoholic (AFL) and non-alcoholic fatty liver (NAFL) are characterized by lipid deposition in hepatocytes. The diagnosis of steatosis is made when lipid deposition exceeds 5% of hepatocytes, while involvement of more than 50% is called "fatty liver ". An additional inflammatory reaction leads to alcoholic (ASH) or non-alcoholic steatohepatitis (NASH). Steatohepatitis is present when both inflammatory infiltrates of mixed cells in the small liver lobules as well as liver cell injury in terms of ballooning can be detected.Liver biopsy represents the "gold standard" for confirming diagnosis and determining inflammatory activity and potential fibrosis of fatty liver disease.The differential diagnosis of ASH-NASH cannot be made on the basis of histological criteria alone. Steatosis, inflammatory changes and hepatocytic injury can be semiquantified as a "Brunt Score" or "NAS" (NAFLD activity score), providing the basis on which to decide whether or not steatohepatitis is present.People at increased risk of developing a fatty liver possess an increased risk of developing chemotherapy-associated steatohepatitis (CASH).Histologically, pediatric NASH differs from adult NASH and is often only clinically manifest through a mild if persistent elevation in transaminases.
Asunto(s)
Hígado Graso Alcohólico/patología , Hígado Graso/patología , Biopsia/métodos , Consenso , Diagnóstico Diferencial , Hígado Graso/clasificación , Hígado Graso/diagnóstico , Hígado Graso Alcohólico/clasificación , Hígado Graso Alcohólico/diagnóstico , Hepatocitos/patología , HumanosRESUMEN
Previous studies have shown that plasma membrane compounds are involved in the contact-dependent inhibition of growth of human diploid fibroblasts. The purification of the active plasma membrane glycoprotein is described in this report. The glycoprotein has an apparent molecular mass of 60-70 kD and, due to differential sialylation, isoelectric points between pH 5.5. and 6.2. Treatment with sialidase yielded one spot in two-dimensional gel electrophoresis with an isoelectric point of 6.3. After removal of the N-glycosidically linked oligosaccharide chains, the apparent molecular mass is reduced by approximately 22 kD. Treatment was diluted NaOH, which removes the O-glycosidically linked portion of oligosaccharides, resulted in a reduction of the apparent molecular mass by approximately 5 kD. The addition of 50 ng/ml of this glycoprotein-for which the term "contactinhibin" is proposed-in immobilized form to sparsely seeded human fibroblasts resulted in a reversible 70-80% inhibition of growth. The inhibition was not confined to human fibroblasts as other cells were also inhibited, with the exclusion of transformed cells, which are refractory to contactinhibin. The inhibitory activity was abolished by treatment with beta-galactosidase or glycopeptidase F, indicating that the glycan moiety is the biologically active part of the molecule. Confluent cultures treated with antibodies raised against contactinhibin were released from the contact-dependent inhibition of growth. In addition to enhanced saturation density, these cultures exhibited a crisscross growth pattern and the formation of foci. Immunocytochemical studies showed that contactinhibin was associated with vimentin. Furthermore, contactinhibin was found to be not expressed in a species- or organ-specific manner.
Asunto(s)
Comunicación Celular , División Celular , Inhibición de Contacto , Glicoproteínas de Membrana/fisiología , Animales , Línea Celular , Membrana Celular/fisiología , Membrana Celular/ultraestructura , Células Cultivadas , Cromatografía en Gel , Citoesqueleto/fisiología , Citoesqueleto/ultraestructura , Electroforesis en Gel de Poliacrilamida , Fibroblastos/citología , Fibroblastos/fisiología , Humanos , Glicoproteínas de Membrana/aislamiento & purificación , Microscopía Electrónica , Peso MolecularRESUMEN
Hepatocyte growth factor-scatter factor (HGF-SF) is a pleiotropic cytokine with mito-, morpho-, and motogenic effects on a variety of epithelial and endothelial cells. HGF-SF activity is mediated by the c-met protooncogene, a membrane-bound tyrosine kinase. Here, we demonstrate that both genes are expressed in developing and adult mammalian brains. HGF-SF mRNA is localized in neurons, primarily in the hippocampus, the cortex, and the granule cell layer of the cerebellum, and it is also present at high levels in ependymal cells, the chorioid plexus, and the pineal body. c-met is expressed in neurons, preferentially in the CA-1 area of the hippocampus, the cortex, and the septum, as well as in the pons. In the embryonic mouse, brain HGF-SF and c-met are expressed as early as days 12 and 13, respectively. Neuronal expression of HGF-SF is evolutionary highly conserved and detectable beyond the mammalian class. Incubation of septal neurons in culture with HGF-SF leads to a rapid increase of c-fos mRNA levels. The results demonstrate the presence of a novel growth factor-tyrosine kinase signaling system in the brain, and they suggest that HGF-SF induces a functional response in a neuronal subpopulation of developing and adult CNS.
Asunto(s)
Encéfalo/metabolismo , Factor de Crecimiento de Hepatocito/biosíntesis , Neuronas/metabolismo , ARN Mensajero/análisis , Proteínas Tirosina Quinasas Receptoras/biosíntesis , Animales , Secuencia de Bases , Encéfalo/embriología , Células Cultivadas , Desarrollo Embrionario y Fetal , Regulación de la Expresión Génica/efectos de los fármacos , Factor de Crecimiento de Hepatocito/análisis , Factor de Crecimiento de Hepatocito/genética , Factor de Crecimiento de Hepatocito/farmacología , Humanos , Ratones , Datos de Secuencia Molecular , Factores de Crecimiento Nervioso/farmacología , Neuronas/efectos de los fármacos , Proteínas Proto-Oncogénicas c-met , ARN Mensajero/genética , Ratas , Ratas Wistar , Proteínas Tirosina Quinasas Receptoras/análisis , Proteínas Tirosina Quinasas Receptoras/genética , Proteínas Recombinantes/farmacología , Transcripción GenéticaRESUMEN
BACKGROUND AND STUDY AIMS: Confocal endomicroscopy is a unique novel tool for in vivo histology in humans. Due to limitations imposed by the form of the equipment and by sterilization workflows, its use has been limited to the gastrointestinal tract so far. We have developed a rigid miniaturized probe for confocal endomicroscopy of the human liver during laparoscopy. PATIENTS AND METHODS: To assess the feasibility and potential clinical value of this new system (diameter 6.3 mm), 25 patients with liver disease were examined during routine minilaparoscopy under conscious sedation. RESULTS: Subsurface serial images (from surface to 250 microm) were generated in real time after fluorescein injection, permitting visualization of hepatocytes, bile ducts, sinusoids, and collagen fibers in vivo. Typical appearances of liver diseases were identified. Confocal diagnosis of moderate-to-severe steatosis and pericellular fibrosis correlated well with histopathologic analysis of subsequent biopsies (83.3 % and 84.6 %, respectively). In addition, intra-abdominal structures such as gallbladder, omentum, and stomach were analyzed by endomicroscopy. CONCLUSIONS: A miniaturized imaging system for confocal laparoscopy allowed in vivo microscopic analysis of healthy and diseased human liver for the first time during ongoing minilaparoscopy. Although such in vivo imaging does not yet compete with conventional histopathology, this novel confocal laparoscopy system may be of future relevance for immediate morphodynamic analysis in liver disease and the targeting of biopsies in vivo.
Asunto(s)
Hígado/patología , Microscopía Confocal/métodos , Adulto , Anciano , Animales , Hígado Graso/patología , Femenino , Humanos , Cirrosis Hepática/patología , Hepatopatías/patología , Masculino , Persona de Mediana Edad , PorcinosRESUMEN
Histopathology plays an important role in the diagnosis of graft complications following liver transplantation (LTX) and includes the diagnosis of underlying liver disease, assessment of the donor liver before LTX and control biopsies after LTX. Within the early period after LTX (time zero and first month) preservation/reperfusion injury, as well as hyperacute and acute rejection may occur. Surgical vascular or biliary complications can cause parenchymal morphological changes. Within 12 months following LTX, histological signs of opportunistic infections and chronic rejection are frequent findings and disease recurrence is typical beyond the first year. Drug toxicity in liver allograft recipients can be induced by immunosuppressive therapy or other drugs. A high percentage of adult patients reveal histological features of idiopathic chronic hepatitis 6 months after LTX. Histopathological differential diagnosis of the combined underlying causes or complications is often difficult.
Asunto(s)
Hepatopatías/patología , Hepatopatías/cirugía , Trasplante de Hígado/patología , Biopsia , Diagnóstico Diferencial , Hepatitis/patología , Humanos , Inmunosupresores/efectos adversos , Trasplante de Hígado/inmunología , Complicaciones Posoperatorias/patología , Daño por Reperfusión/patología , Donantes de TejidosRESUMEN
New findings have been made in recent years on the various forms of the hepatitis virus in terms of disease course, its etiopathogenetic link with comorbidities and the definition of new forms in Central Europe. Epstein-Barr virus (EBV)- and cytomegalovirus (CMV)-induced hepatitis may occur in the so-called sero-negative group of hepatitis and direct demonstration of the viral genome in paraffin liver tissues is required to confirm the diagnosis. Since diagnosis of autoimmune hepatitis in daily practice may be difficult, a scoring system with simplified criteria has recently been developed.
Asunto(s)
Hepatitis Autoinmune/patología , Hepatitis Viral Humana/patología , Carcinoma Hepatocelular/clasificación , Carcinoma Hepatocelular/diagnóstico , Carcinoma Hepatocelular/patología , Infecciones por Citomegalovirus/clasificación , Infecciones por Citomegalovirus/diagnóstico , Infecciones por Citomegalovirus/patología , Diagnóstico Diferencial , Progresión de la Enfermedad , Infecciones por Virus de Epstein-Barr/clasificación , Infecciones por Virus de Epstein-Barr/diagnóstico , Infecciones por Virus de Epstein-Barr/patología , Hepatitis B Crónica/clasificación , Hepatitis B Crónica/diagnóstico , Hepatitis B Crónica/patología , Hepatitis C Crónica/clasificación , Hepatitis C Crónica/diagnóstico , Hepatitis C Crónica/patología , Hepatitis D/clasificación , Hepatitis D/diagnóstico , Hepatitis D/patología , Hepatitis E/clasificación , Hepatitis E/diagnóstico , Hepatitis E/patología , Hepatitis Autoinmune/clasificación , Hepatitis Autoinmune/diagnóstico , Hepatitis Viral Humana/clasificación , Hepatitis Viral Humana/diagnóstico , Humanos , Hígado/patología , Neoplasias Hepáticas/patologíaRESUMEN
The first half of the twentieth century was marked by noticeable changes in society, medicine and institutions. The interrelationship between these factors can be demonstrated by clinical mass sources, in particular by patient and autopsy records, which historians have so far neglected. A longitudinal study was made where data, such as gender and age as well as clinical and anatomical-pathological diagnoses were collected, based on 250 autopsy records from 8 selected years between 1914 and 1960. The random samples taken showed clear differences in gender relationship and in age composition and in addition they revealed a significant reduction in mortality caused by inflammation and an increase of chronic diseases, such as tumors or cardiac-circulation ailments. The origin of this development is seen in medical progress as well as in institutional and ideological circumstances, therefore multidimensional reciprocal effects must be thoroughly analyzed.
Asunto(s)
Registros Médicos , Patología/historia , Anatomía/historia , Autopsia/historia , Femenino , Alemania , Historia del Siglo XIX , Humanos , MasculinoRESUMEN
Targeted therapies present an interesting treatment option in prostate cancer. The aim of our study was to analyze the expression profile of several molecular markers that are candidates for targeted therapy in patients with progressive androgen-independent prostate cancer (AIPC). Based on the expression profile, the efficacy of a combination therapy with a signal transduction inhibitor (STI) and docetaxel was evaluated.Tumor tissue obtained from biopsy of the prostate or lymph node and visceral metastasis was analyzed for the immunohistochemical expression of epidermal growth factor receptor (EGFR), platelet-derived growth factor receptor beta (PDGFRbeta), Her-2/neu, c-KIT, and vascular endothelial growth factor (VEGF). Patients with positive staining of one or more markers were treated with the corresponding STI and docetaxel.Fifty-one patients were included in the protocol, of whom 43 (84.3%) presented with progressive AIPC after first-line chemotherapy. Forty-six of these 51 patients (90.2%) showed expression of one or more of the analyzed markers. Expression of EGFR was found in 61.2%, PDGFRbeta in 57.1%, Her-2/neu in 16.3%, c-KIT in 25.0%, and VEGF in 74.5%. After request for cost coverage, 8/51 patients received the combination therapy and were evaluated for response. Four of the eight patients (50%) showed a decline in prostate-specific antigen of > or =50%, and median survival time was 13.5 months at a median follow-up of 23.6 (11-35) months.The results show that expression of molecular targets is found in about 90% of patients with AIPC. Based on the expression profile, an individual treatment strategy can be applied to each patient. Further clinical studies should determine the clinical efficacy of molecular targeted therapy in patients with AIPC.
Asunto(s)
Anticuerpos Monoclonales/administración & dosificación , Protocolos de Quimioterapia Combinada Antineoplásica/administración & dosificación , Biomarcadores de Tumor/genética , Neoplasias Hormono-Dependientes/tratamiento farmacológico , Neoplasias Hormono-Dependientes/genética , Neoplasias de la Próstata/tratamiento farmacológico , Neoplasias de la Próstata/genética , Proteínas Tirosina Quinasas/antagonistas & inhibidores , Receptores Androgénicos/genética , Taxoides/administración & dosificación , Anticuerpos Monoclonales/efectos adversos , Anticuerpos Monoclonales Humanizados , Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Benzamidas , Bevacizumab , Biopsia , Cetuximab , Progresión de la Enfermedad , Docetaxel , Resistencia a Antineoplásicos , Perfilación de la Expresión Génica , Humanos , Mesilato de Imatinib , Ganglios Linfáticos/patología , Masculino , Neoplasias Hormono-Dependientes/patología , Piperazinas/administración & dosificación , Piperazinas/efectos adversos , Estudios Prospectivos , Próstata/patología , Antígeno Prostático Específico/sangre , Neoplasias de la Próstata/patología , Pirimidinas/administración & dosificación , Pirimidinas/efectos adversos , Receptores Androgénicos/efectos de los fármacos , Taxoides/efectos adversos , TrastuzumabRESUMEN
The detection of single tumor cells or tumor cell clusters represents an important issue in intraoperative frozen section analysis. For example, surgical margins may be evaluated in order to minimize the number of additional operations. Furthermore, intraoperative diagnosis of lymph node micrometastasis (LNM) may help to define the area of appropriate lymph node dissection. In addition to haematoxylin and eosin (H&E)-stained sections, immunohistochemical detection of single tumor cells or cell clusters may be helpful in this context. The aim of this study was to evaluate the clinical significance, reliability and sensitivity of intraoperative rapid immunostaining of frozen sections. Therefore, we compared the results of rapid immunohistochemical staining of frozen sections and paraffin sections applying the EnVision and Histofine(R) detection systems. In a prospective immunohistochemical study, paraffin and frozen sections of 20 gastric cancer specimens were analyzed. Paraffin as well as frozen sections were stained immunohistochemically applying the EnVision and Histofine detection systems. As primary antibodies, AE1/AE3 (anti-cytokeratin), EMA (anti-MUC1) and B lymphocyte marker anti-CD20 were applied. The rapid immunostaining procedure was able to be completed within 10-13 min. Rapid immunohistochemical staining of frozen and paraffin sections of the same tumors resulted in comparable immunoreactivity. The rapid EnVision and Histofine procedures allowed immunostaining of frozen sections in less than 13 min. These methods can represent useful additional tools in routine surgical pathology and research, enabling a more accurate frozen section diagnosis compared to staining with H&E alone. Intraoperative rapid immunostaining can be a simple and useful technique to detect LNM.
Asunto(s)
Adenocarcinoma/patología , Neoplasias Gástricas/patología , Anciano , Anticuerpos/química , Antígenos CD20/inmunología , Antígenos de Neoplasias/inmunología , Femenino , Secciones por Congelación , Humanos , Inmunohistoquímica/métodos , Masculino , Mucina-1 , Mucinas/inmunología , Adhesión en ParafinaRESUMEN
AIM: The aim of this prospective study was to evaluate the clinical and prognostic impact of immunohistochemically assessed uPA and PAI-1 in patients with gastric cancer. METHODS: This prospective study analyzed specimens obtained from 105 gastric cancer patients who underwent gastrectomy with extended lymphadenectomy. The immunohistochemical expression of uPA and PAI-1 was studied semiquantitatively in the tumor epithelium and was correlated with the clinicopathological features of each patient. RESULTS: Univariate analysis revealed no statistically significant association of uPA levels with pT and pN category (p=0.655 and 0.053, respectively), grading (p=0.374), depth of tumor invasion (p=0.665), UICC classification (p=0.21) and the Laurén classification (p=0.578). PAI-1 expression showed no statistically significant correlation with pT, pN and M category (p=0.589, 0.414, and 0.167, respectively), grading (p=0.273), and the Laurén classification (p=0.368). Only the UICC classification was significantly correlated with PAI-1 (p=0.016). Kaplan-Meier analysis revealed no significant association of uPA and PAI-1 with overall survival (p=0.0929 and 0.0870, respectively). CONCLUSIONS: Our results could not verify any prognostic value of uPA and PAI-1 levels in patients with gastric carcinoma. Therefore, the uPA-system as a biologically defined prognostic marker to identify high-risk gastric cancers should be applied with caution. However, considering the number of patients involved and the borderline level of significance observed in this study, a larger number of events may have resulted in significant differences.
Asunto(s)
Adenocarcinoma/diagnóstico , Biomarcadores de Tumor/análisis , Inhibidor 1 de Activador Plasminogénico/análisis , Neoplasias Gástricas/diagnóstico , Activador de Plasminógeno de Tipo Uroquinasa/análisis , Adenocarcinoma/patología , Adulto , Anciano , Femenino , Humanos , Inmunohistoquímica , Masculino , Persona de Mediana Edad , Pronóstico , Estudios Prospectivos , Neoplasias Gástricas/patología , Análisis de SupervivenciaAsunto(s)
Neoplasias Renales/diagnóstico , Nefroma Mesoblástico/diagnóstico , Osificación Heterotópica/diagnóstico , Enfermedades Raras/diagnóstico , División Celular/fisiología , Tejido Conectivo/patología , Diagnóstico Diferencial , Humanos , Lactante , Riñón/patología , Neoplasias Renales/patología , Neoplasias Renales/cirugía , Imagen por Resonancia Magnética , Masculino , Nefrectomía , Nefroma Mesoblástico/patología , Nefroma Mesoblástico/cirugía , Osificación Heterotópica/patología , Osificación Heterotópica/cirugía , Ultrasonografía , Tumor de Wilms/diagnóstico , Tumor de Wilms/patologíaRESUMEN
The specific tissue distribution of melanoma-associated ganglioside II3-alpha-N-acetylneuraminosyl-alpha 2----8-N-acetylneuraminosyllactosylceramide (GD3) was studied on 175 cryopreserved, unfixed human tissue sections with R-24 mouse monoclonal antibody by indirect immunoperoxidase staining. A striking specificity of monoclonal antibody R-24 for malignant melanoma tissues was established. Ganglioside GD3 was detected in all 21 tissue sections of 21 patients with primary melanoma and in all 37 probes of 24 patients with metastatic malignant melanoma. The majority of tumor cells in the samples of primary malignant melanoma expressed GD3; however, GD3 expression was more heterogeneous in samples of metastatic lesions even in different metastases of the same patient. Of 11 nevi, 9 reacted with monoclonal antibody R-24, while melanocytes in the basal layer of normal skin stained only weakly and irregularly. None of the 32 normal and 12 fetal human tissue types were R-24 positive, but a strong cytoplasmic staining was observed with single cells in the dermis and in the interstitial tissue of the gastrointestinal tract, in the interlobular septa of the thymus, and in other distinct locations. Only two malignant carcinoid tumors of 38 nonmelanomatous tumors tested reacted with monoclonal antibody R-24.